Quantcast

Industry news that matters to you.  Learn more

Archives for June 2010

TGen partner, PBS-Bio, makes first breakthrough drug analysis

Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday. These patents cover two different diagnostic tests for identifying human patients likely to respond to treatment with tivozanib, AVEO’s highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, which is currently being evaluated in a global Phase 3 clinical trial, TIVO-1, in patients with renal cell cancer (RCC).

Multiple biomarker index useful only in asymptomatic patients with mild atherosclerosis

A multiple biomarker index, one that includes markers of inflammation, is only modestly associated with increased risks of coronary heart disease and cardiovascular disease in asymptomatic patients, according to the results of a new study [1]. The increased risk of events for patients with a biomarker score above the median occurs mainly in those with a mild amount of existing atherosclerosis, according to investigators.

UC San Diego Brain Tumor Treatment Program Launches Personalized Biomarker Clinical Study

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.

Early Biomarker of Insulin Resistance and Glucose Intolerance Identified in a Nondiabetic Population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population. Co-authored by physicians and scientists from EGIR (European Group for the Study of Insulin Resistance) and Metabolon, the paper, “alpha-hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population”, appears on the PLoS One website (doi: (May 28th 2010)).